D Bottke1, D Bartkowiak2, C Bolenz3, T Wiegel2. 1. Fachbereich Strahlentherapie und Radioonkologie, MVZ Klinikum Esslingen GmbH, Hirschlandstraße 97, 73730, Esslingen a. N., Deutschland. d.bottke@klinikum-esslingen.de. 2. Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm, Albert-Einstein-Straße 23, 89081, Ulm, Deutschland. 3. Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm, Prittwitzstraße 43, 89075, Ulm, Deutschland.
Abstract
BACKGROUND: There are numerous randomized trials to guide the management of patients with localized (and metastatic) prostate cancer, but only a few (mostly retrospective) studies have specifically addressed node-positive patients. Therefore, there is uncertainty regarding optimal treatment in this situation. Current guidelines recommend long-term androgen deprivation therapy (ADT) alone or radiotherapy plus long-term ADT as treatment options. OBJECTIVES: This overview summarizes the existing literature on the use of radiotherapy for node-positive prostate cancer as definitive treatment and as adjuvant or salvage therapy after radical prostatectomy. In this context, we also discuss several PET tracers in the imaging evaluation of patients with biochemical recurrence of prostate cancer after radical prostatectomy. As for definitive treatment, retrospective studies suggest that ADT plus radiotherapy improves overall survival compared with ADT alone. These studies also consistently demonstrated that many patients with node-positive prostate cancer can achieve long-term survival - and are likely curable - with aggressive therapy. RESULTS: The beneficial impact of adjuvant radiotherapy on survival in patients with pN1 prostate cancer seems to be highly influenced by tumor characteristics. Men with ≤ 2 positive lymph nodes in the presence of intermediate- to high-grade disease, or positive margins, and those with 3 or 4 positive lymph nodes are the ideal candidates for adjuvant radiotherapy (plus long-term ADT) after surgery. CONCLUSION: There is a need for randomized trials to further examine the potential role of radiotherapy as either definitive or adjuvant treatment, for patients with node-positive prostate cancer.
BACKGROUND: There are numerous randomized trials to guide the management of patients with localized (and metastatic) prostate cancer, but only a few (mostly retrospective) studies have specifically addressed node-positive patients. Therefore, there is uncertainty regarding optimal treatment in this situation. Current guidelines recommend long-term androgen deprivation therapy (ADT) alone or radiotherapy plus long-term ADT as treatment options. OBJECTIVES: This overview summarizes the existing literature on the use of radiotherapy for node-positive prostate cancer as definitive treatment and as adjuvant or salvage therapy after radical prostatectomy. In this context, we also discuss several PET tracers in the imaging evaluation of patients with biochemical recurrence of prostate cancer after radical prostatectomy. As for definitive treatment, retrospective studies suggest that ADT plus radiotherapy improves overall survival compared with ADT alone. These studies also consistently demonstrated that many patients with node-positive prostate cancer can achieve long-term survival - and are likely curable - with aggressive therapy. RESULTS: The beneficial impact of adjuvant radiotherapy on survival in patients with pN1 prostate cancer seems to be highly influenced by tumor characteristics. Men with ≤ 2 positive lymph nodes in the presence of intermediate- to high-grade disease, or positive margins, and those with 3 or 4 positive lymph nodes are the ideal candidates for adjuvant radiotherapy (plus long-term ADT) after surgery. CONCLUSION: There is a need for randomized trials to further examine the potential role of radiotherapy as either definitive or adjuvant treatment, for patients with node-positive prostate cancer.
Authors: Lars Budäus; Sami-Ramzi Leyh-Bannurah; Georg Salomon; Uwe Michl; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber; Clemens Rosenbaum Journal: Eur Urol Date: 2015-06-25 Impact factor: 20.096
Authors: Firas Abdollah; R Jeffrey Karnes; Nazareno Suardi; Cesare Cozzarini; Giorgio Gandaglia; Nicola Fossati; Marco Bianchi; Stephen A Boorjian; Maxine Sun; Pierre I Karakiewicz; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2013-09-27 Impact factor: 20.096
Authors: Fritz H Schröder; Karl-Heinz Kurth; Sophie D Fossa; Wytse Hoekstra; Peter P Karthaus; Linda De Prijck; Laurence Collette Journal: Eur Urol Date: 2008-09-17 Impact factor: 20.096
Authors: Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså Journal: Lancet Date: 2008-12-16 Impact factor: 79.321
Authors: Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: Malcolm D Mason; Wendy R Parulekar; Matthew R Sydes; Michael Brundage; Peter Kirkbride; Mary Gospodarowicz; Richard Cowan; Edmund C Kostashuk; John Anderson; Gregory Swanson; Mahesh K B Parmar; Charles Hayter; Gordana Jovic; Andrea Hiltz; John Hetherington; Jinka Sathya; James B P Barber; Michael McKenzie; Salah El-Sharkawi; Luis Souhami; P D John Hardman; Bingshu E Chen; Padraig Warde Journal: J Clin Oncol Date: 2015-02-17 Impact factor: 44.544